Is Mounjaro now an FDA-approved heart medicine?
Yes. On August 28, 2026, the FDA approved Mounjaro (tirzepatide) to lower the risk of heart attack, stroke, and cardiovascular death in adults with type 2 diabetes and established atherosclerotic cardiovascular disease. It joins semaglutide, liraglutide, and dulaglutide as a heart-protection option in this group. What tipped the approval wasn't a lower heart-attack rate. It was fewer deaths.
The approval rests on SURPASS-CVOT, the largest cardiovascular trial tirzepatide has been through. It asked a narrow question: could tirzepatide hold its own against a drug that already lowers heart events? On the primary endpoint, it could. Whether it actually beat that drug is more complicated, and that's why some cardiologists read the result as catch-up and others as an upgrade.
The trial behind the label
SURPASS-CVOT randomized 13,165 adults with type 2 diabetes and established atherosclerotic cardiovascular disease to tirzepatide or dulaglutide, and followed them for a median of about four years. The comparator matters. Most cardiovascular outcomes trials in diabetes have used placebo. This one used dulaglutide, which already has an approved heart-protection claim from its own trial, REWIND. Tirzepatide had to hold its own against a drug that works.
On the primary composite of cardiovascular death, non-fatal heart attack, and non-fatal stroke, 12.2% of tirzepatide participants had an event versus 13.1% on dulaglutide. That gap met the bar for noninferiority but not superiority. Read strictly, tirzepatide is as good as dulaglutide on those events, not better.
Why it got approved anyway
Two other results carried the case. All-cause mortality was about 16% lower on tirzepatide, an endpoint that doesn't turn on adjudication rules or where you draw the line between fatal and non-fatal. A broader cardiorenal composite, which added coronary revascularization, hospitalization for heart failure, and adverse kidney outcomes to the standard three, also favored tirzepatide by about 16%. A drug that lowers deaths and a wider set of cardiorenal events, even without beating its rival on the tight definition, is doing real work.
A prespecified indirect analysis bridged SURPASS-CVOT with the placebo arm of REWIND to estimate how tirzepatide would compare against placebo. That estimate landed near a 28% relative reduction. It's bridging math rather than a head-to-head trial, but it lines up with real-world data showing broadly similar cardiovascular outcomes between tirzepatide and semaglutide.
Where tirzepatide fits with the older heart-protective GLP-1s
Tirzepatide isn't the first incretin drug approved to protect the heart in type 2 diabetes. Liraglutide, semaglutide, and dulaglutide each earned an FDA cardiovascular indication after their own pivotal trials. Tirzepatide is the newest member of that group, with the added edge of stronger glucose and weight lowering.
| Drug | Pivotal trial | Effect on heart attacks and strokes | Comparator |
|---|---|---|---|
| Tirzepatide (Mounjaro) | SURPASS-CVOT | About the same as comparator | Dulaglutide |
| Semaglutide (Ozempic) | SUSTAIN-6 | About 26% lower | Placebo |
| Liraglutide (Victoza) | LEADER | About 13% lower | Placebo |
| Dulaglutide (Trulicity) | REWIND | About 12% lower | Placebo |
What the approval changes for you
If you have type 2 diabetes and established heart disease, tirzepatide is now a defensible first choice, especially when you also need better glucose control or more weight loss than the older GLP-1 drugs can deliver. It's the most potent drug in the class on both HbA1c and weight, and those metabolic gains plausibly contribute to the mortality signal.
If you're already on semaglutide, liraglutide, or dulaglutide and doing well, there's no reason to switch. All three have longer safety records, all three cut heart events, and swapping for a marginally different point estimate is motion without purpose.
If you have type 2 diabetes without cardiovascular disease, or obesity without diabetes, the new indication doesn't apply to you yet. A larger trial in obesity without diabetes (SURMOUNT-MMO, about 15,000 participants) is testing whether tirzepatide reduces heart events in that group, and its result will decide whether the claim extends further.
The tradeoffs are the class's. Nausea, vomiting, and diarrhea during dose escalation are common and mostly mild to moderate. Pancreatitis and gallbladder events are rare. The label still carries a boxed warning about thyroid C-cell tumors seen in rodents. For someone who fits the trial population, four years of follow-up support the benefit outweighing those risks.
This approval doesn't crown tirzepatide as the best heart-protective diabetes drug. It gives it a seat at a table already set by three others, with the strongest evidence being fewer deaths, not fewer heart attacks. For someone with type 2 diabetes and a worried cardiologist, that seat is worth taking.